Vaccines are the biological preparation used for stimulating antibody production to activate immune system against diseases such as influenza, Hepatitis A, Hepatitis B, Human Papillomavirus, Polio, and Rabies. High prevalence of infectious disease and increasing governmental initiative for implementing nationalized vaccination programme are expected to drive growth of the vaccine market, whereas high developmental cost of vaccine is expected to hamper growth of the vaccine market. For instance, according to the Centers for Disease Control and Prevention (CDC), 2015, flu vaccinations prevented an around 1.9 million flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated hospitalizations, representing 6.5% lowering of disease burden in the U.S.
Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1500
The global disease control and prevention vaccine market is projected to witness significant growth over the forecast period, owing to rapid advancements in technology for development of novel vaccines such as recombinant and cell-based technologies, resulting in increasing production of the vaccines. For instance, in 2018, collaboration between Austrian biotech Themis Bioscience and Oslo-based Coalition for Epidemic Preparedness Innovations (CEIP). CEIP will fund US$ 37.5 million for vaccine development for five years. Moreover, governmental bodied supports the research and development program leading to the development of improved form of presently available vaccines. For instance, in 2015, a National Institute of Allergy and Infectious Disease scientists engineered a protein to maintain the specific shape of the viral spike, stimulating the immune system to produce powerful anti-HIV antibodies. However, manufacturing cost as well as large gap between demand and supply leading to hike in pricing is expected to hinder the growth of disease control and prevention vaccination market.
Increasing Governmental Initiatives for Immunization Programs is Driving Growth of the Disease Control and Prevention Vaccine Market
Governmental and non-governmental organization partners are working together to provide better immunization to population for complete disease eradication. For instance, the Global Polio Eradication Initiative was a public-private partnership between five governmental agencies – the World Health Organization (WHO), Rotary International, the US Centers for Disease Control and Prevention (CDC), the United Nations Children’s Fund (UNICEF) and the Bill & Melinda Gates Foundation, aiming at polio eradication worldwide. The program was funded US$ 15 billion in the period 1988 – 2017, provided by public and private donors and 2013 – 2019 requirement was projected to US$ 7 billion. Furthermore, organization such as Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH) have partnered with the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to support development of advanced influenza vaccines. Such governmental approaches are expected to augment the growth of global disease control and prevention vaccine market over the forecast period (2017-2025). However, high cost of vaccine development is expected to restrain growth of the disease control and prevention vaccine market.
According to Access to Medicine Foundation index, 2017, vaccine market is dominated by four major players, collectively referred as ‘big four’: GSK, Merck & Co., Inc., Pfizer, and Sanofi. Big four contribute to 80% of the global vaccine revenue. Players vary significantly by portfolio and pipeline size. Other major players operating in market include AstraZeneca PLC, Sinovac Biotech Ltd., Astellas Pharma Inc., Serum Institute of India Pvt. Ltd., and Daiichi Sankyo.